The Efficacy of Radiofrequency Ablation for Bone Tumors Unsuitable for Radical Excision

Jun Sung Koo, So Hak Chung, Jun Sung Koo, So Hak Chung

Abstract

Background: Bone tumors can cause severe pain and poor quality of life due to recurrence and non-achievement of complete remission after surgery, chemotherapy, or radiotherapy. Radiofrequency ablation (RFA) can be considered for minimally invasive treatment of bone tumors that are difficult to radically excise. In this study, RFA was performed for bone tumors that were difficult to radically excise and did not respond to surgery, chemotherapy, or radiotherapy due to their large sizes and/or locations. The purpose of this study was to retrospectively analyze the clinical characteristics and survival rates of bone tumors after RFA and provide one more treatment option for the future.

Methods: There were 43 patients with bone tumors who underwent percutaneous RFA at our hospital from April 2007 to October 2017. The median age of the patients was 59 years (range, 31-75 years), and the median follow-up duration was 67.2 months (range, 10.2-130.5 months). Of the 43 patients, 26 were male and 17 were female. Thirty-four cases were metastatic bone tumors, 5 were chordomas, 3 were osteosarcomas, and 1 was a giant cell tumor. Pain and functional ability of the patients were evaluated using a visual analog scale (VAS) and the Musculoskeletal Tumor Society (MSTS) functional scoring system, respectively. Scores were recorded preoperatively, 1 week postoperatively, and 4 weeks postoperatively. The 1-year, 2-year, and 5-year survival rates were evaluated using the Kaplan-Meier method.

Results: The mean VAS score was 8.21 preoperatively. The mean VAS score at 1 week, 4 weeks, 12 weeks, and 24 weeks postoperatively were 3.91, 3.67, 3.31, and 3.12, respectively. The mean preoperative MSTS score was 64.0% (range, 32%-87%). The mean postoperative MSTS score was 71.0% (range, 40%-90%). The 1-year, 2-year, and 5-year survival rates were 95.3%, 69.8%, and 30.2%, respectively.

Conclusions: As per our study findings, RFA was effective in reducing pain and improving functional ability of patients with bone tumors that were difficult to radically excise.

Keywords: Bone neoplasms; Radiofrequency ablation.

Conflict of interest statement

CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported.

Copyright © 2021 by The Korean Orthopaedic Association.

Figures

Fig. 1. Preoperative (Preop) and postoperative (Postop)…
Fig. 1. Preoperative (Preop) and postoperative (Postop) visual analog scale (VAS) scores. Group 1: metastatic bone tumor, Group 2: chordoma, Group 3: osteosarcoma, Group 4: giant cell tumor.
Fig. 2. The Kaplan-Meier curve showing the…
Fig. 2. The Kaplan-Meier curve showing the survival rate of all patients.
Fig. 3. The Kaplan-Meier curve showing the…
Fig. 3. The Kaplan-Meier curve showing the survival rates of different groups of patients.

References

    1. Volkmer D, Sichlau M, Rapp TB. The use of radiofrequency ablation in the treatment of musculoskeletal tumors. J Am Acad Orthop Surg. 2009;17(12):737–743.
    1. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities: part II. J Vasc Interv Radiol. 2001;12(10):1135–1148.
    1. Rosenthal DI, Hornicek FJ, Torriani M, Gebhardt MC, Mankin HJ. Osteoid osteoma: percutaneous treatment with radiofrequency energy. Radiology. 2003;229(1):171–175.
    1. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. Radiology. 2000;217(3):633–646.
    1. Ahrar K. The role and limitations of radiofrequency ablation in treatment of bone and soft tissue tumors. Curr Oncol Rep. 2004;6(4):315–320.
    1. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;(286):241–246.
    1. Wagshal AB, Pires LA, Huang SK. Management of cardiac arrhythmias with radiofrequency catheter ablation. Arch Intern Med. 1995;155(2):137–147.
    1. Tillotson CL, Rosenberg AE, Rosenthal DI. Controlled thermal injury of bone: report of a percutaneous technique using radiofrequency electrode and generator. Invest Radiol. 1989;24(11):888–892.
    1. Rosenthal DI, Alexander A, Rosenberg AE, Springfield D. Ablation of osteoid osteomas with a percutaneously placed electrode: a new procedure. Radiology. 1992;183(1):29–33.
    1. Dupuy DE, Liu D, Hartfeil D, et al. Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial. Cancer. 2010;116(4):989–997.
    1. Callstrom MR, Charboneau JW, Goetz MP, et al. Painful metastases involving bone: feasibility of percutaneous CT-and US-guided radio-frequency ablation. Radiology. 2002;224(1):87–97.
    1. Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol. 2004;22(2):300–306.
    1. Neeman Z, Patti JW, Wood BJ. Percutaneous radiofrequency ablation of chordoma. AJR Am J Roentgenol. 2002;179(5):1330–1332.
    1. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol. 2000;174(2):323–331.
    1. Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142(1):10–19.
    1. Lencioni R, Cioni D, Crocetti L, Bartolozzi C. Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl. 2004;10(2 Suppl 1):S91–S97.
    1. Davis KW, Choi JJ, Blankenbaker DG. Radiofrequency ablation in the musculoskeletal system. Semin Roentgenol. 2004;39(1):129–144.
    1. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999;230(1):1–8.
    1. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med. 2000;6(5):521–528.
    1. Mannion RJ, Woolf CJ. Pain mechanisms and management: a central perspective. Clin J Pain. 2000;16(3 Suppl):S144–S156.
    1. Jang JH, Park YK. The comparision of the radiofrequency ablasion therapy with vertebroplasty and radiotherapy in metastatic spine tumor. J Korean Orthop Assoc. 2011;46(2):122–129.
    1. Gronemeyer DH, Schirp S, Gevargez A. Image-guided radiofrequency ablation of spinal tumors: preliminary experience with an expandable array electrode. Cancer J. 2002;8(1):33–39.
    1. Nakatsuka A, Yamakado K, Maeda M, et al. Radiofrequency ablation combined with bone cement injection for the treatment of bone malignancies. J Vasc Interv Radiol. 2004;15(7):707–712.
    1. Thanos L, Mylona S, Galani P, et al. Radiofrequency ablation of osseous metastases for the palliation of pain. Skeletal Radiol. 2008;37(3):189–194.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe